Menú

Inicio Revista Formación Noticias Agenda Categorías Quiénes Somos

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II)

O. Fernández, Y. Aladro, R. Arroyo, Ll. Brieva, M.C. Calles-Hernández, P. Carrascal, M. Comabella, L. Costa-Frossard, S. Eichau, J.A. García-Merino, R. Ginestal, I. González, G. Izquierdo, M.L. Martínez-Ginés, J.E. Meca-Lallana, M.M. Mendibe-Bilbao, A. Oterino, J.M. Prieto, J. Río, Ll. Ramió-Torrentà, L. Romero-Pinel, N. Téllez, A. Rodríguez-Antigüedad Journal 70(11) ● Publication date 01/06/2020 ● Revisión ● Views 2440 ● Downloads 177 Castellano English

Download PDF
ESP Download PDF
ENG Autoevaluación Add citation to
your library

Share this article on social networks:

Search in PubMed

By author

Fernandez O Aladro Y Arroyo R Brieva Ll Calles-Hernandez MC Carrascal P Comabella M Costa-Frossard L Eichau S Garcia-Merino JA Ginestal R Gonzalez I Izquierdo G Martinez-Gines ML Meca-Lallana JE Mendibe-Bilbao MM Oterino A Prieto JM Rio J Ramio-Torrenta Ll Romero-Pinel L Tellez N Rodriguez-Antiguedad A

By keyword

Disease-modifying therapy ECTRIMS Multiple sclerosis Post-ECTRIMS Stem cell therapies Symptomatic treatment

See in PubMed

Current article Related articles

Vea nuestros másteres

[REV NEUROL 2020;70:417-429] PMID: 32436209 DOI: https://doi.org/10.33588/rn.7011.2020122

INTRODUCTION. Like every year, after the ECTRIMS Congress, renowned Spanish neurologists who are experts in multiple sclerosis presented the main novelties in research in this field at the Post-ECTRIMS Meeting.

AIM. To summarise the content presented at the 12th edition of the Post-ECTRIMS Meeting, which took place in September 2019 in Sevilla and is presented in two parts. DEVELOPMENT. In this second part, the most recent evidence on the use of disease-modifying treatments during pregnancy is presented. Details are provided concerning the results of phase 3 clinical trials conducted to evaluate the efficacy and safety of two potential disease-modifying treatments for relapsing-remitting multiple sclerosis: ponesimod and ofatumumab. For the progressive forms, both available disease modifying treatments and others still in the research phase are reviewed. In the field of stem cell therapies, the article includes the results of the only clinical trial carried out to date comparing patients with relapsing-remitting multiple sclerosis treated with autologous haematopoietic stem cell transplantation and those treated with disease-modifying therapies. There are no important developments as regards symptomatic treatments, although the European Academy of Neurology has published a guide on palliative care. The various sources of information that collect pharmacovigilance data in the post-marketing setting are reviewed.

CONCLUSIONS. Patients diagnosed in recent years tend to have less severe multiple sclerosis, probably due to the fact that it is diagnosed in its milder stages together with the steady increase in the number of treatments available.

Keywords Disease-modifying therapy ECTRIMS Multiple sclerosis Post-ECTRIMS Stem cell therapies Symptomatic treatment Classified in Esclerosis múltiple

Search in PubMed

By author

By keyword

Disease-modifying therapy ECTRIMS Multiple sclerosis Post-ECTRIMS Stem cell therapies Symptomatic treatment

See in PubMed

Current article Related articles

Search in PubMed

By author

By keyword

Disease-modifying therapy ECTRIMS Multiple sclerosis Post-ECTRIMS Stem cell therapies Symptomatic treatment

See in PubMed

Current article Related articles

12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (II)

Share this article on social networks:

Search in PubMed

By author

By keyword

See in PubMed

Abierta la Preinscripción

Máster en Neuropsicología de las Altas Capacidades Intelectuales

6ª Edición

Abierta la Matrícula

Máster en Neurociencia Experimental y Clínica

6ª Edición

Search in PubMed

By author

By keyword

See in PubMed

Search in PubMed

By author

By keyword

See in PubMed